Hatta Kosuke, Tanaka Ryota, Kimura Kenjiro, Yamashita Naoki, Li Jie, Kunisada Terufusa, Ishizawa Takeaki
Department of Hepato-Biliary-Pancreatic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
R&D Technology Center, Tamron Co., Ltd., Saitama, Japan.
Biosci Trends. 2025 Jul 4;19(3):328-336. doi: 10.5582/bst.2025.01113. Epub 2025 Jun 14.
Indocyanine green (ICG)-C9, a novel cyanine dye developed by the Center for Biosystems Dynamics Research at RIKEN, provides significant advantages over conventional ICG due to its detectability via shortwave-infrared (SWIR) fluorescence imaging. Unlike standard ICG, ICG-C9 facilitates SWIR imaging and displays therapeutic potential when conjugated with antibodies in vivo, suggesting broader applicability across various cancer types. This study evaluated the efficacy of SWIR fluorescence imaging with ICG-C9 in comparison with existing near-infrared (NIR) imaging techniques. We assessed excretion kinetics and the relationship between excitation and fluorescence wavelengths for ICG-C9 and ICG following intravenous administration in BALB/c-nu mice. Tumor uptake was evaluated using a cell-line-derived subcutaneous tumor model from HuH-7 cells, representing hepatocellular carcinoma. Variables including dose, administration route, and exposure time were optimized for comparison. Maximum fluorescence intensity for ICG-C9 was observed with an excitation wavelength of 915 nm and fluorescence emission wavelengths >950 nm within the SWIR spectrum. Both ICG-C9 and ICG followed similar excretion pathways, involving hepatic uptake and biliary excretion. Tumor uptake of ICG-C9 was confirmed under similar conditions to ICG. ICG-C9 demonstrates promising potential as an alternative to NIR fluorescence imaging with ICG, offering unique properties that may enhance imaging capabilities. However, further research is required to establish its clinical applicability and broader therapeutic utility.
吲哚菁绿（ICG）-C9是由日本理化学研究所生物系统动力学研究中心开发的一种新型菁染料，由于其可通过短波红外（SWIR）荧光成像进行检测，因此与传统ICG相比具有显著优势。与标准ICG不同，ICG-C9便于进行SWIR成像，并且在体内与抗体偶联时显示出治疗潜力，这表明其在各种癌症类型中具有更广泛的适用性。本研究评估了与现有的近红外（NIR）成像技术相比，使用ICG-C9进行SWIR荧光成像的效果。我们在BALB/c-nu小鼠静脉注射后评估了ICG-C9和ICG的排泄动力学以及激发波长与荧光波长之间的关系。使用源自HuH-7细胞的皮下肿瘤模型（代表肝细胞癌）评估肿瘤摄取情况。为了进行比较，对包括剂量、给药途径和暴露时间在内的变量进行了优化。在激发波长为915 nm且荧光发射波长>950 nm（在SWIR光谱范围内）时观察到ICG-C9的最大荧光强度。ICG-C9和ICG均遵循相似的排泄途径，包括肝脏摄取和胆汁排泄。在与ICG相似的条件下证实了ICG-C9的肿瘤摄取。ICG-C9作为ICG近红外荧光成像的替代物显示出有前景的潜力，具有可能增强成像能力的独特特性。然而，需要进一步研究以确定其临床适用性和更广泛的治疗效用。
